Press Release – November 28, 2016

Viable Canadian Alzheimer’s Treatment Halted

Affordable Alternative Could Be Available in Months

Toronto, ON – November 28, 2016 … With the recently announced failure of Alzheimer’s drugs leaving dementia and Alzheimer’s patients with diminished hope, there is a viable Canadian solution that could be made available in months, not years. With proper funding, BioVerity Inc., is poised to launch human testing and produce a natural health product to address aging and cognitive decline within 6 to 7 months. Recently published research findings indicate its natural 31-ingredient supplement may successfully treat dementia, Alzheimer’s and several other neurological diseases.

How does it work?

The BioVerity formula addresses five key factors associated with aging: oxidative stress, insulin resistance, mitochondrial activity, inflammation, and cell membrane integrity. Results from over a decade of scientific research studies with mice has obtained remarkable results to date. The mice maintained youthful levels of learning, physical activity and appearance into extreme old age. In fact, increases in mouse “health span” meant that animals remained youthful for a significant part of their lives.

The animals used in this study (a mouse model of accelerated aging) had widespread loss of more than 50% of their brain cells, severely impacting multiple regions of the brain by one year of age, the human equivalent of severe Alzheimer’s disease. When an identical population of mice were fed the formula over the course of several months. Researchers found that the BioVerity formula completely eliminated the severe brain cell loss and totally abolished cognitive decline.

Researchers were able to dramatically shorten product development time through the innovative step of simultaneously testing 31 scientifically targeted ingredients. Typically, drugs or ingredients in supplements are tested in isolation, one at a time on live animals, each taking three or more years to evaluate. Instead, BioVerity researchers created a formula of ingredients that had already been tested in isolation and that showed promise against key factors believed to cause Alzheimer’s and age related diseases. By not testing the ingredients one at a time, BioVerity was able to develop the formula decades earlier than previously imagined and is ready to bring its solution forward to human trials.

“We require $3 million to test and begin marketing this very promising nutraceutical treatment with humans. Success could help treat over 600,000 Canadians suffering from devastating neurological conditions like Alzheimer’s, ALS and Parkinson’s,” said Max Carbone, CEO of BioVerity Inc. “As BioVerity is a natural formula and not a drug, it could be produced and marketed across North America in just 6 to 7 months. We want to ensure human tolerability before we market a general health formula at the lowest possible price. We would then extend testing with various university and medical researchers to validate benefits for specific diseases in humans.”

BioVerity is hoping to generate media coverage for the breakthrough to reach high net worth potential investors.

“We are looking to attract a socially conscious backer who is interested in keeping this a Canadian venture while earning a healthy financial and social return along the way,” added Carbone. “With their help, we can commercialize viable treatments for aging and neurological diseases that impact millions of Canadians.”

Unlike current costly Alzheimer’s and dementia drugs, BioVerity aims to price its product at the $100 a month mark.

“The research suggests there is tremendous potential with this formula to help people who are suffering from catastrophic neurological diseases,” says Dr. Lemon, who conducted the work with co-author Dr. Vadim Aksenov, a post-doctoral fellow from a top ranked Ontario research university. “We know this because mice experience the same basic cell mechanisms that contribute to neuro-degeneration that humans do.”

About BioVerity:

BioVerity Inc. was established in 2013 to commercialize evidence-based scientific learning and intellectual property on complex dietary supplements. The company is based in Toronto and is led by: Max Carbone, CEO, Joseph Castaldi, COO, and Dr. Nicholas Rupcich, Chief Science Officer.

The BioVerity formula was developed and tested by three internationally recognized university scientists: Dr. David Rollo, Dr. Douglas Boreham and Dr. Jennifer Lemon. The supplement is considered significant in light of the Alzheimer Association’s position that, “Currently, there is no cure for Alzheimer’s. The drugs currently available to treat the disease are highly ineffective and cause many negative side effects. There are few, if any, promising drugs in development and they are years away from being proven”.

BioVerity Press Release

9th July, 2014
FOR IMMEDIATE RELEASE
ANTI-AGING RESEARCH TO BE COMMERCIALIZED
Toronto, Canada

BioVerity Inc. is pleased to announce an exclusive collaborative research and license agreement with McMaster University in Hamilton, ON, to commercialize a complex dietary supplement aimed to ameliorate processes associated with aging. The formulation was developed by three McMaster University scientists – Dr. David Rollo, Dr. Douglas Boreham and Dr. Jennifer Lemon.

“I kept on hearing about McMaster’s research on aging in the media,” said Max Carbone, CEO of Bioverity. “After a segment on the national news in 2012(1) I talked to my father, a pioneering wellness physician, to ask him what he thought. He agreed with what he heard and encouraged me to speak with the researchers. A year later with key partners Bioverity was founded.”

For over a decade, the McMaster team has worked on optimizing a formulation of food-based ingredients that synergistically address five key aspects associated with aging: oxidative stress, insulin resistance, mitochondrial activity, inflammation, and cellular membrane integrity. Results from research with mice and insects obtained remarkable results. Both insects and mice given the formula had significantly increased longevity (27% in a mouse model of accelerated aging(2)) and mice also maintained youthful levels of learning(3), physical activity and appearance into advanced old age(4). In fact, increases in mouse “healthspan” meant that animals remained youthful for a greater proportion of their lives.

“The formulation has years of science behind it,” said Joe Castaldi, VP Bioverity. “We plan on working with the McMaster team to pursue the full potential of the formula.”

This license agreement enables BioVerity Inc. to quickly move forward with the global commercialization of the complex dietary formula under the brand name BioVerity. Although the formulation consists of compounds known and tested to be safe for human consumption, the company is in the process of raising capital to complete human clinical trials to further validate these health claims in the coming months. Bioverity has been in discussions with several groups to establish an initial U.S. test market, with a subsequent rollout in both Canada and the United States.

BioVerity Inc. was established in 2013 to commercialize McMaster’s evidence-based scientific learning and intellectual property on complex dietary supplements. The company is based in Toronto and is led by: Max Carbone, CEO, Joseph Castaldi, VP, and Dr. Nicholas Rupcich, Chief Science Officer.

To contact BioVerity Inc. please call 1-800-382-1959.


(1) CBC News. Aging slowed in mice with supplement mix. 2 January 2012.
(2) Lyn J, Aksenov V, LeBlanc Z, and Rollo CD.* 2012. Life history features and aging rates: Insights from intra-specific patterns in the cricket Acheta domesticus. Evol. Biol. 39: 371-387. (IF: 3.61)
(3) Aksenov V, Khanna P, Long J, Liu J, Szechtman H, Matravadia S, Rollo CD.* 2012. A complex dietary supplement improves spatial learning, increases brain size and improves mitochondrial activity in aging mice. AGE: DOI: 10.1007/s11357-011-9325-2 (Impact Factor (IF): 6.28.
(4) Lemon, J.A., Boreham, D.R., Rollo, C.D. 2003. A dietary supplement abolishes age-related cognitive decline in transgenic mice expressing elevated free radical processes. Exp. Biol. Med. 228:800-810.